Source comparison
Comparative Data: CJC-1295 No DAC vs GHRP-2 and Other Secretagogues
CJC-1295 No DAC GHRH analog. Binds GHRH receptor, stimulates endogenous GH release from pituitary somatotrophs 2–7× baseline at 90–120 min (Teichman 2005) 6–8 days Once weekly Longest-acting GHRH analog without albumin binding; produces sustained IGF-1 elevati
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC
- GHRH analog. Binds GHRH receptor, stimulates endogenous GH release from pituitary somatotrophs
- 2–7× baseline at 90–120 min (Teichman 2005)
- 6–8 days
- Once weekly
- Longest-acting GHRH analog without albumin binding; produces sustained IGF-1 elevation but requires subcutaneous injection
- GHRP-2
- Ghrelin mimetic. Binds GHS-R1a receptor, stimulates GH release and appetite signalling
- 5–10× baseline at 30–60 min (Bowers 1999)
- 20–30 minutes
- 2–3× daily
- Potent GH pulse but short duration; synergises with CJC-1295 but causes transient hunger and cortisol elevation
- Ipamorelin
- Selective GHS-R1a agonist. Stimulates GH without cortisol or prolactin elevation
- 3–5× baseline at 30–45 min (Raun 1998)
- 2 hours
- Cleanest secretagogue profile; minimal side effects but requires frequent dosing and doesn't sustain IGF-1 elevation
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic. GHS-R1a agonist with 24-hour activity
- 2–3× baseline (chronic elevation)
- 24 hours
- Once daily
- Only oral option; increases appetite and water retention; chronic GH elevation may reduce pulsatility benefits
- The comparison reveals a trade-off between pulse amplitude and duration. GHRP-2 and Ipamorelin produce sharper GH spikes but require multiple daily doses to maintain effect. CJC-1295 without DAC produces a moderate GH pulse that sustains IGF-1 for nearly a week with a single injection. The 2006 Ionescu study tested combination protocols (CJC-1295 + GHRP-2) and found additive effects. The GHRH analog primes the pituitary while the ghrelin mimetic triggers immediate release, producing GH levels 10–15× baseline. That synergy is why many research protocols pair CJC-1295 with a short-acting secretagogue rather than using either alone. Labs designing multi-peptide stacks for metabolic or recovery studies can explore synergistic compound pairings like the FAT Loss Stack, which combines complementary peptide mechanisms under a single research protocol.